How Osteopore Won Vietnam’s Public Hospital Tenders for Orthopaedic Innovation

Osteopore Breaks Ground in Vietnam Public Hospitals

Osteopore Limited, an Australian-Singaporean regenerative medicine company specialising in 3D-printed bioresorbable implants, has successfully secured tender bids to supply its orthopaedic products to two major public hospitals in Vietnam. This milestone follows the company’s earlier regulatory approvals in Singapore and Vietnam, positioning Osteopore to capitalize on a rapidly growing orthopaedic market in the Asia Pacific region.

The awarded tenders, valued at approximately AUD 90,000 over the first year, include Osteopore’s flagship product for high tibial osteotomy (HTO); a surgical procedure to realign the knee; alongside other bone grafting applications. These products leverage Osteopore’s patented technology, which fabricates micro-structured scaffolds designed to promote natural bone regeneration while gradually dissolving, reducing complications associated with permanent implants.

Tapping into a High-Growth Orthopaedic Market

The timing of these tender wins aligns well with robust market forecasts. The HTO segment in the Asia Pacific is projected to grow at a compound annual growth rate (CAGR) of 9.2%, with procedures expected to reach 35,000 annually by 2025. Meanwhile, the broader bone grafting market is anticipated to expand steadily, driven by increasing demand for advanced orthopaedic solutions.

Vietnam’s orthopaedic device market itself is forecasted to grow at a CAGR of 7.68% between 2024 and 2028, fueled by an aging population and rising prevalence of musculoskeletal conditions. Osteopore’s entry into two major public hospitals thus represents a strategic foothold in a market ripe for innovation and growth.

Looking Ahead – Execution and Expansion

Osteopore’s next steps involve working closely with its local distribution partner to finalise logistics and supply arrangements, a process expected to conclude within three months. CEO Dr Lim Yujing expressed confidence in the company’s clinical outcomes and market strategy, highlighting plans to extend commercial progress beyond Vietnam to other identified markets.

While the initial tender value is modest, these contracts serve as a critical validation of Osteopore’s technology and market approach. The company’s unique 3D printing process and bioresorbable materials differentiate it in a competitive landscape, potentially paving the way for larger contracts and broader adoption across Asia Pacific.

Investors and industry watchers will be keen to monitor how Osteopore leverages this momentum, particularly in securing follow-on tenders and scaling supply capabilities to meet growing demand.